Results 181 to 190 of about 67,861 (213)

CT-P13: design, development, and place in therapy. [PDF]

Drug Des Devel Ther, 2017
Gabbani T, Deiana S, Annese V.
europepmc   +1 more source

Biosimilars: what's around the corner? [PDF]

Frontline Gastroenterol, 2015
Russell RK, Irving P, Probert C.
europepmc   +1 more source

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. [PDF]

RMD Open, 2019
Lindström U, Glintborg B, Di Giuseppe D, Nordström D, Aarrestad Provan S, Gudbjornsson B, Askling J, Lund Hetland M, Aaltonen K, Krogh NS, Geirsson AJ, Jacobsson LTH.   +11 more
europepmc   +1 more source

Sobre los mitos: Análisis formal y simbólico de El Paraíso Perdido [PDF]

, 2006
Mora Millán, María Luisa
core   +1 more source

Cosmonoticias [PDF]

, 2014
Carbajo Hijarrubia, Juan
core   +3 more sources

A bibliometric analysis of the global research on biosimilars. [PDF]

J Pharm Policy Pract, 2018
Hernández-Vásquez A, Alarcon-Ruiz CA, Bendezu-Quispe G, Comandé D, Rosselli D.   +4 more
europepmc   +1 more source

Encuentro con pensadores: a propósito de Protágoras [PDF]

, 2015
Muñoz Box, Fernando
core   +1 more source

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars. [PDF]

Front Pharmacol
Zeng Z, Lin H, Jiang M, Yuan J, Li X, Jia Y, Yang L, Zhang H.   +7 more
europepmc   +1 more source

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. [PDF]

Curr Rheumatol Rep, 2017
Moots R, Azevedo V, Coindreau JL, Dörner T, Mahgoub E, Mysler E, Scheinberg M, Marshall L.   +7 more
europepmc   +1 more source